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Arguments in favour of the incorporation of traditional 
health practitioners (THPs) into the overall health 
system are highly persuasive,1,2 especially in the context 
of South Africa’s HIV epidemic and the inability of the 
public health sector to cover the health care needs 
of all HIV-positive patients.3 However, even those 
who support a more significant role for THPs have 
articulated a set of minimum standards that must be 
met as a pre-condition to this step, including:2,4,5
n    the systematic evaluation of African traditional 
medicines (ATMs)
n    the standardisation, processing and packaging of 
traditional medicines
n    training on HIV to ensure a high level of prevention 
(of HIV) and care (of patients)
n    the development of mechanisms to regulate the 
practice of traditional healing.
Over the past 3 years, Arvir Technologies, a public-
funded company that was established to validate 
and register a herbal medicine for the treatment of 
HIV based on ATMs, have been working on the first of 
these standards, namely the evaluation of ATMs, and 
more specifically on three plant extracts the use of 
which for the treatment of HIV/AIDS by THPs has been 
reported previously.6,7 This project has raised a number 
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Background. A large proportion of HIV-positive South Africans regularly consult traditional health practitioners 
(THPs) for their health care needs, despite evidence of negative interactions with antiretrovirals (ARVs) and no 
published peer-reviewed clinical evidence for the efficacy of traditional medicines in the treatment of HIV. We 
investigated the dominant practices of THPs towards HIV-positive patients and whether these practices have 
changed following widespread public awareness campaigns covering HIV and its treatment.
Method. The study used a semi-structured interviewer-administered questionnaire in the home language of the 
interviewee. A total of 52 THPs from four provinces (Gauteng, Limpopo, KwaZulu-Natal and Eastern Cape) were 
interviewed. Of the respondents 38% were based in the rural areas, and 69% classified themselves as inyangas, 
the remainder being sangomas. 
Findings. All the THPs in the survey offered treatment for HIV, although only 20% claimed to be able to cure the 
disease; 88% prepared their own medication, mostly from plant material, and sold their products as aqueous 
extracts in labelled bottles. None of these products had been systematically evaluated, and there was generally 
no record keeping, either of the patient or of the medicine itself. Quality control practices such as expiry dates, 
controlled storage conditions and batch records were totally unknown in our sample. Only 38% of the THPs 
had received training on HIV/AIDS, although 75% believed that they were well informed about the disease. Our 
own assessment was that only 50% had a working knowledge of HIV; more disturbingly, 37% believed that only 
traditional medicines should be used for its treatment and a further 50% believed that traditional medicines 
and ARVs can be taken simultaneously.
Interpretation. Despite ongoing public educational campaigns on HIV, some of which have specifically targeted 
THPs, the care of HIV-positive patients continues to be compromised by the traditional sector. Although some 
progress is evident, THP approaches to HIV treatment fail to conform to minimum standards proposed by the 
World Health Organization and other organisations, and represent a considerable challenge to the integration 
of THPs with the biomedical sector and the antiretroviral treatment programme in South Africa.
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of important questions about the curative approaches 
and practices of THPs, and the supply channels for the 
plant-based ingredients of their medicines, as follows:
n    Several studies8-11 have reported widespread 
consultation of THPs by people living with HIV/
AIDS, reflecting a high level of trust in both 
traditional methods and ATMs; what is the basis 
of this support, and is there any evidence for the 
efficacy claims of THPs in their treatment of HIV 
(anecdotal or clinical)?
n    The traditional health sector is known to be highly 
divergent; what are the dominant treatment 
approaches, and what are the trends in this 
regard?
n    Regulation of the sector has recently been 
implemented through the promulgation of the 
Traditional Health Practitioners Act (No. 22 of 2007); 
to what extent has the Act changed the profile and 
conduct of the sector, and could this facilitate the 
introduction of a fully validated herbal medicine?
n    Similarly, there have been several educational 
programmes to assist THPs to improve their 
understanding of the disease and their alignment 
with the goals of the antiretroviral (ARV) treatment 
(ART) programme in South Africa; have the 
programmes been successful in this regard? 
n    Allopathic and traditional medicines are typically 
seen as highly divergent; what is the level of 
interaction between the two sectors (biomedical 
and traditional health care), and are inter-sectoral 
referrals increasing?
In our research, we have attempted to answer these 
questions. The underlying intention was to develop an 
understanding of whether and how we could engage 
with the traditional health sector, and to define better 
approaches for improving the biomedical/traditional 
health interface.
METHODS
The study was undertaken using a semi-structured 
interview-administered questionnaire. It was conducted 
in four provinces of South Africa, and a total of 52 
THPs were interviewed (Table I). The interviewees were 
identified by asking members of the community for 
information on the prominent THPs; once identified, 
the researcher explained the purpose of the study to 
the practitioner and requested permission for the 
interview.
The questionnaire covered a range of areas including 
membership of a professional association (as prescribed 
by the Traditional Health Practitioners Act), the extent 
of training on HIV/AIDS already completed (including 
treatment with ARVs), the level of knowledge about 
the prevention, incidence, diagnosis and biomedical 
treatment of HIV/AIDS, the number of HIV-positive 
patients being treated, interaction with the biomedical 
sector (referrals and diagnosis), and the nature of the 
THP’s treatment for HIV (including quality control of 
prescribed medicines).
RESULTS 
AN OVERVIEW OF THP PRACTICE AND HIV/AIDS
The majority of THPs (69%) in our study classified 
themselves as inyangas (herbalists); in other words, the 
source of their healing is considered to derive from their 
use of medicinal plants, as opposed to the approach of 
the sangomas (diviners), who rely more on divination 
for their healing approach. Diviners have different 
names in different regions of South Africa, depending 
on the dominant regional culture, including izangoma 
in Zulu, amagqira in Xhosa, ngaka in Northern Sotho 
and mungome in Venda, although the majority of 
South Africans refer collectively to this group of THPs 
as ‘sangomas’.12,13
Except in the Eastern Cape and Gauteng (where the 
figure was only 50%), most of the THPs in this study 
(79%) were registered with a local THP association, 
although no practitioners were as yet registered in 
terms of the Traditional Health Practitioners Act (No. 
22 of 2007). This and other observations lead to the 
inevitable conclusion that implementation of the Act 
since its promulgation has been almost non-existent in 
all regions of the country. 
Not surprisingly, all the THPs in our study regularly 
see HIV-positive patients (between 3 and 10 patients 
per week). The THPs stated that most of their patients 
were women, but believed that males are the dominant 
transmitters of HIV/AIDS. In their view, the gender 
differences make it difficult to treat couples (either 
discordant or both HIV positive) because men do not 
talk openly about their HIV status and are therefore less 
likely to seek treatment.
TRAINING AND KNOWLEDGE OF HIV/AIDS
Only 38% of the THPs had received HIV/AIDS training 
of one or more days; as a result, their knowledge of 
the disease was limited and influenced by a high level 
of suspicion of non-traditional interventions and 
biomedical strategies. For instance, some THPs still 
believe that there is no such thing as HIV/AIDS and 
continue to associate the symptoms of the disease with 
cultural notions of sickness, e.g. makgome in Pedi and 
isifusenhlu in Zulu, which require the performance of 
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Province No. of THPs participating
Eastern Cape                   13
Gauteng                   11
KwaZulu-Natal                   15
Limpopo                   13
TABLE I. DISTRIBUTION OF INTERVIEWEES  
BY PROVINCE
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a cleansing ceremony for healing. In our assessment, 
which was based on answers to a standard set of 
questions about HIV, its treatment and its prevention, 
only 50% of respondents have a working knowledge of 
HIV, although 75% feel that they were well informed 
about the disease and its symptoms (Fig. 1). 
Although limited in the sample, THPs’ ignorance and 
mistrust of condom use as a prevention strategy is of 
great concern. Some opinions expressed in this regard 
were:
    ‘In the past there were no such things as condoms or 
HIV in our society; ever since condoms were brought 
to us there is a high rate of HIV/AIDS because they are 
infested with diseases. Proof is in that oil lubricant.’
    ‘Condoms are contributing to the spread of HIV/
AIDS, for an example if you put condom in a sunny 
condition or pour hot water on it, you will notice 
worms coming out of that experiment. That is the 
very same worm they are referring to as AIDS.’
DIAGNOSIS AND TREATMENT
For the diagnosis of HIV, at least 69% of the THPs stated 
that they refer their patients to the biomedical sector 
for testing and require a positive HIV test result before 
the patient can start treatment (Fig. 2). The remaining 
practitioners use various approaches including THP 
observation, patient self-diagnosis and ‘dreams and 
guidance from the ancestors’. 
The modality of the treatment, even within the two 
separate groups of inyangas and sangomas, varied 
considerably. The latter often require patients to 
undergo a rigorous in-house cleansing and treatment 
routine. For instance, a THP in rural Eastern Cape, who 
sees HIV-positive clients from all over the country, has 
built a hospice in his yard for his patients. Inyangas, 
on the other hand, follow an approach of an initial 
consultation with fortnightly or monthly follow-
up visits, depending on how quickly the prescribed 
treatments are completed.
Of THPs in our sample 73% prescribe a herb-based 
solution called imbiza (Zulu) which is sold in a 2 
litre or 750 ml bottle and is claimed to cleanse or 
purify the blood. It was apparent from the research 
that a wide range of plants collected from different 
geographical regions and ecological systems are used 
in the preparation of the imbiza. It is claimed that 
the practitioners’ understanding of plant medicinal 
properties is based on an extensive knowledge of their 
traditional use, obtained from the ancestors and passed 
down through oral tradition. Almost all the THPs (88%) 
prepare their own medicine using the natural plant 
ingredients and a hot water infusion process.
The questionnaire specifically avoided detailed 
questions about the exact identity of the ingredients 
in order to protect any potential intellectual property. 
In some cases, however, this information was provided 
without any prompting and included a number of 
plants, the antiviral and immunomodulatory properties 
of which have already been reported.7,14-17 The plants 
were sourced from the local area (collected personally 
by the THP) and also from markets trading in medicinal 
plants (mostly in the major urban areas).
The recommended dosage varies according to a number 
of factors, as follows:
n    stage of the disease (chronic stage  125 ml 3 times 
a day; bed-ridden patients 250 ml 3 times a day)
Fig. 2. THPs referring patients to clinics for HIV testing.
Fig. 1. Extent of knowledge (THPs and interviewer assessment). 
Are you well informed about HIV?  
(self-assessment by THP)
Extent of knowledge  
(assessment of interviewer)
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n    affordability to the patient (unemployed patients 3 
times a day; employed patients 4 times a day) 
n    distance from which the patient comes (patients 
from far places are given a 5 litre bottle and take 
60 ml of the medicine 3 times a day).
The cost of medicine also varies from a minimum of 
R200 to a maximum of R2 800 (Fig. 3). The treatment 
cost is determined by the following:
n    the local reputation of the THP and hence patient 
belief in the efficacy of ATMs (the better the 
reputation, the more expensive the treatment)
n    the variety of herbs used (the more herbs, the 
higher the price)
n    the location of the practice (prices in the rural 
areas are generally lower).
All the THPs in our survey were confident about the 
efficacy of their treatment for both HIV (20% claim to 
be able to cure HIV; the remainder to treat the infection) 
and HIV/AIDS-related opportunistic infections, 
although we were shown no recorded evidence for these 
claims. When asked to show evidence to support their 
statement, a number of claims were made including 
verbal reports of increases in CD4 count and patient 
well-being. As noted later, only 17% of THPs keep any 
patient records and track HIV status.
Based on our own research and the work of other drug 
discovery organisations, the basis for claims relating to 
most of the plants is highly questionable. This statement 
is supported by two main arguments derived from an 
extensive evaluation of the antiretroviral properties of 
plant extracts, as follows:6
n    Most of the plant-based traditional medicines 
are prepared through hot water infusion 
of dried plant material (leaves, roots, bark, 
etc.); the resultant solutions contain at 
most 0.5% of extracted solids, so that a 
250 ml dose in turn contains the equivalent of 
1.25 g solid material. The concentration of the active 
ingredient(s) varies considerably depending on the 
plant itself and in many cases these ingredients 
have not been properly identified. However, our 
work with three local products indicates that the 
active ingredient(s) are at most 5% by mass of the 
total extract. In other words, a patient taking a 
250 ml dose of a herbal infusion (the highest dose 
recorded in our study) will be consuming not more 
than 63 mg of active ingredient(s) per dose, or 188 
mg per day. 
n    A wide range of specific antiretroviral activities for 
plant-based natural products (and other compounds) 
has been reported in the literature,14-17 but even the 
most active natural compounds have activities no 
better than between 1 and 5 μM based on a range of 
in vitro cell-based assays. These values are between 
100 and 1 000 times less active than the equivalent 
allopathic medicines such as zidovudine, efavirenz 
and tenofovir (Tables II and III). In other words, a 
patient taking a traditional medicine for the treatment 
of HIV will be receiving on average less than 0.5% 
of a therapeutic dose. This calculation does make 
some assumptions about the bio-availability of the 
natural product(s) but is a reasonable estimate of 
effective dose and its comparison with the registered 
antiretroviral products.
In summary, although many plant extracts have a 
measurable level of antiretroviral activity (as determined 
in cell-based assays), this activity is many times lower 
than that of the synthetic products. Considering that 
HIV patients on traditional medicines are taking on 
average less than 150 mg of the active compound(s), the 
net dose is only a fraction of the required therapeutic 
dose, and the possibility that a level of viral control is 
achieved is remote.
QUALITY CONTROL, EFFICACY AND PATIENT RECORDS
Most of the THPs (69%) claimed that their medication 
is of good quality and that there is no need for batch 
records, expiry dates or quality assessment of the 
ingredients/final product, which are standard concepts 
in the preparation of allopathic medicines. When asked 
to explain the reason for the difference, the THPs noted 
that ‘unlike Western medicine our medicine doesn’t 
have any preservatives; therefore there is no need 
to include expiry dates because natural plants don’t 
expire’. In addition, very few THPs label their products.
In terms of patient records, as has been stated 
previously, only 17% of THPs keep any form of records, 
with the actual proportion varying from 26% in 
Gauteng to 8% in the Eastern Cape. As a result, no 
conclusive results can be derived from analysis of the 
treatment outcomes since these cannot be supported 
by documented evidence including health assessments, 
viral loads and other indicators of disease progression 
in HIV-positive patients. It is clear that this is one 
important area in which training can play a major role 
in upgrading the quality of care being provided by THPs 
in South Africa.
Fig. 3. Cost of traditional medicines for the treatment of HIV.
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INTERACTION WITH THE BIOMEDICAL HEALTH CARE SECTOR
When asked about the possibility of interaction with 
other health practitioners, THPs believed that nurses 
undermine their work and do not accept the efficacy of 
their treatment. As a result, THPs are reluctant to refer 
their patients to the biomedical sector for ART. A similar 
observation has been reported in other studies.19
The THPs indicated that unlike nurses and doctors 
they do not take the patients off ART but encourage 
their patients to take both ATMs and ARVs, since they 
believe that ARVs are also made from muti (Fig. 4). 
At least 50% of the THPs participating in our study 
showed little interest in learning or working with 
the biomedical sector and several openly criticised 
the allopathic approach, making statements such as 
‘doctors kill patients with their ARVs’. 
DISCUSSION
The results of this study have shown that many THPs 
offer treatment for HIV/AIDS despite a somewhat 
limited understanding of the virus, the symptoms of 
infection and its treatment. Furthermore, the medicines 
are expensive relative to both patient incomes and the 
biomedical equivalents, have no recorded evidence of 
efficacy, and are not quality controlled in most respects.
Despite these factors, many patients continue to consult 
THPs for HIV-related illness and to use traditional 
medicines. The persistence of this support is due to 
many factors, including:
n    an ongoing belief in the efficacy of traditional 
medicines, which is considered to have been passed 
down through generations from the ancestors
Drug name Class IC50 (μM) TC50 (μM) Therapeutic index Dosage (mg/d)
Efavirenz NNRTI 0.0015 80 53 333 600
Maraviroc EI 0.001 25 20 161 600
Lamivudine NRTI 0.07 360 5 143 300
Nevirapine NNRTI 0.029 320 11 034 400
Stavudine NRTI 0.03 100 3 333 60
Zidovudine NRTI 0.002 32 16 000 600
Emtricitabine NRTI 0.04 150 3 750 200
Tenofovir NRTI 0.005 29 5 800 300
Indinavir PI 0.014 32 2 286 1 600
*Data for all the synthetic and natural products have been obtained directly from the National Institute of Health’s database,18 which lists the anti-HIV activity of 
over 170 000 compounds based on information in the literature. Where possible the values for the PBMC assay have been used.
NNRTI = non-nucleoside reverse transcriptase inhibitor; EI = entry inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor. 
TABLE II. ANTIRETROVIRAL ACTIVITY AND ACTUAL DOSAGE OF SEVERAL SYNTHETIC PRODUCTS* 
     Estimated  
Plant Active ingredient IC50 (μM) TC50 (μM) Therapeutic index dosage (mg/d)
Syzygium claviflorum Betulinic acid 1.4 13 9 60 000
Lobostemon trigonus6 Unknown (data shown  
 for crude extract) ~2.5 2 000 800 150 000
Curcuma longa Curcumin 5.0 10.0 2 100 000
Inula britannica 3,5-di-O-caffeoylquinic acid 2.0 486 243 40 000
Calophyllum lanigerum Calanolide A 0.1 10 100 8 000
*Data for all the synthetic and natural products have been obtained directly from the National Institute of Health’s database,18 which lists the anti-HIV activity of 
over 170 000 compounds based on information in the literature. Where possible the values for the PBMC assay have been used. 
TABLE III. ANTIRETROVIRAL ACTIVITY AND ESTIMATED DOSAGE OF SEVERAL NATURAL PRODUCTS*
Fig. 4. THPs’ attitudes to ARV treatment.
Can ARVs and ATMs be taken together? Attitude to ARVs
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n    considerable competition between the two 
treatment methodologies, especially by the THPs, 
who openly discredit the conventional sector in 
various ways (referral of a patient to the tertiary 
sector by a THP is in many respects a direct conflict 
of interest)
n    the confidentiality of consulting a traditional healer 
(there is a belief that information such as the 
patient’s HIV status is not secure in the biomedical 
sector)
n    the perceived uncaring, unsympathetic and 
impersonal approach of the biomedical sector to 
patients, which is humiliating and hurtful to the 
patient; doctors are considered to give inadequate 
time to patient consultation
n    the side-effects of ARVs and the fact that these 
medications are not a cure, but have to be taken 
forever
n    lack of regulation in the sector, which encourages 
illegal and opportunistic practices including wild 
claims about treatment efficacy; in some cases the 
more bizarre the treatment, the greater the number 
of patients.
These problems are well known in the sector, and other 
authors have identified a set of minimum standards that 
require urgent implementation.9 Our study has shown 
that little progress has been made with implementation 
of these standards. For instance: 
n    Although all of the THPs claim to treat HIV (and 
20% to cure the disease), none of the treatments 
have been systematically evaluated.
n    The majority (88%) of the THPs interviewed prepare 
their own medication but fail to keep patient 
records or batch data for each preparation. Most of 
the products are sold in labelled bottles as liquids, 
and none have any expiry dates on the labels. The 
opinion of the THPs is that plants do not expire; 
there is therefore no need for proper packaging or 
controlled storage conditions.
n    Of the THPs in our sample, 38% have received 
training on HIV/AIDS and 75% believe that they are 
well informed about the disease; however, based 
on their replies to a few rudimentary questions 
about the disease, our assessment was that only 
50% have a working knowledge of HIV. 
n    Perhaps more disturbingly, 37% believe that only 
ATMs should be used for the treatment of HIV and 
a further 50% believe that both ATMs and ARVs 
can be taken simultaneously.
It is apparent that many THPs play a role in HIV 
prevention and care by referring patients for HIV 
testing (69% of THPs), counselling patients with HIV 
and opportunistic infections, and distributing condoms 
to their patients (62% of the total). Our study makes 
it clear that this role is sub-optimal and could be 
improved through further training and regulation. 
Despite the fact that such regulation has recently been 
implemented by promulgation of the Traditional Health 
Practitioners Act, and that 79% of our sample of THPs 
were registered with a THP association, the Interim 
Traditional Health Practitioners Council of South Africa 
is not yet operational and there is no quality control in 
the sector or enforcement of the legislation. 
With respect to capacity development of THPs, it is 
recommended that training in the following areas 
should be urgently addressed:
n    an understanding of the HIV and the pathology of 
the disease
n    the adoption of safe sexual practices and use of 
biomedical prevention methods
n    quality control of traditional medicines, including 
concepts such as expiry and variability of raw 
materials
n    the dangers of taking ATMs and ARVs together
n    identification of symptoms of HIV infection to assist 
with counselling and treatment, including referral 
to the biomedical sector.
CONCLUSION
In conclusion, it will be a major challenge to use the 
THP network for distribution of a registered herbal 
medicine owing to ongoing ignorance regarding HIV, 
a high rate of illiteracy among THPs especially in rural 
areas, and local cultural beliefs that may prevent 
adoption of biomedical approaches. Nevertheless, the 
extensive network of THPs and ongoing confidence in 
their abilities within local communities suggest that 
efforts to address these challenges will be worthwhile.
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